Cartesian Therapeutics reports additional Descartes-08 retreatment data in myasthenia gravis
Cartesian Therapeutics presented 12-month data from five Phase 2 patients with myasthenia gravis who were retreated with Descartes-08 after symptoms returned. The company said retreated patients showed a mean MG-ADL reduction of 6.6 points at Month 12 and no serious adverse events during retreatment, and it reiterated that Phase 3 AURORA topline data are expected in the first quarter of 2027.
Key points
- Five retreated patients; median interval of 16.6 months from end of initial treatment course to retreatment
- Average MG-ADL reduction of 6.6 (±4.2) points and MGC reduction of 15 (±6.2) points from baseline at Month 12
- No serious adverse events reported during retreatment; no cases of cytokine release syndrome or ICANS
- Phase 3 AURORA topline data expected in 1Q27; BLA filing expected in mid-2027
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.